相关实验视频

Updated: Jan 13, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

作为扩散阶段小细胞肺癌的第一线治疗,阿德布雷利马布的现实研究:一项回顾性研究

Kaili Xu¹, Jian Wang², Zhenhe Weng¹

¹Department of Pulmonary and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.

Frontiers in immunology

|October 29, 2025

概括

第一线阿德布雷利马布免疫疗法在扩散阶段小细胞肺癌 (ES-SCLC) 中显示出有希望的疗效,平均整体存活期为15个月. 然而,表现不佳的状态,高转移性负担和升高的CRP预测了更糟糕的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床研究临床研究

背景情况:

扩散阶段小细胞肺癌 (ES-SCLC) 在历史上预后不佳.
乙化疗提供了有限的生存益处.
在ES-SCLC中对阿德布雷利马布 (抗PD-L1) 加上化疗的真实数据很少.

研究的目的:

在ES-SCLC患者中评估一线阿德布雷利马布基疗法的现实有效性和安全性.
确定影响该患者群体结果的预后因素.

主要方法:

35名ES-SCLC患者接受一线阿德布雷利马布加化疗的回顾性分析.
对客观反应率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS),总生存率 (OS) 和不良事件 (AE) 的评估.
考克斯回归分析以确定预后因素.

主要成果:

目标反应率 (ORR) 为62.8%,疾病控制率 (DCR) 为77.1%.
无进展生存时间 (PFS) 中位数为7.1个月,总生存时间 (OS) 中位数为15.0个月.
东部合作性瘤组绩效状态 (ECOG PS) ≥2,≥2个转移器官和C反应蛋白 (CRP) ≥5毫克/升与较差的结果有关.

结论:

基于阿德布雷利马布的疗法在ES-SCLC中显示出有前途的现实疗效,与临床试验结果一致.
ECOG PS,转移性负担和升高的CRP是劣质PFS和OS的独立预测因素.
密切监测血液毒性和罕见的心脏毒性是必不可少的.

关键词:

阿德布雷利马布里姆是什么意思扩散阶段的小细胞肺癌.作为一线治疗的第一线治疗.预后因素预后因素现实世界的研究研究.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...